February 5, 2010 — Results from 8 clinical trials show that recombinant human thrombin (rThrombin; Recothrom, ZymoGenetics, Inc) is well tolerated in several surgical settings for topical hemostasis ...
SAN FRANCISCO (MarketWatch) -- Omrix Biopharmaceuticals Inc. shares fell 11.6% to $18 in Monday mornings trade after the New York-based company announced positive results from its Phase III clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results